CJS Securities Initiates Coverage on Bioventus (NASDAQ:BVS)

Key Points

• CJS Securities initiated coverage on Bioventus with an "outperform" rating and a $14.00 price target, implying roughly a 49.25% upside; analyst consensus also averages a $14 target with a "Buy" rating (1 Strong Buy, 3 Buy, 1 Hold).
• Bioventus beat Q results with $0.24 EPS vs. $0.22 expected and $157.9M revenue, and provided FY2026 guidance of 0.730–0.770 EPS; the company has a market cap of about $780M and a PE of 28.23.
• Director Michelle Mcmurry‑Heath sold 12,000 shares (a 21% cut to her stake); insiders own about 33% of the stock while institutional investors control roughly 62.94%, including sizable increases by Nantahala Capital.

Equities research analysts at CJS Securities assumed coverage on shares of Bioventus (NASDAQ:BVS - Get Free Report) in a research note issued to investors on Friday, MarketBeat.com reports. The firm set an "outperform" rating and a $14.00 price target on the stock. CJS Securities' price objective would indicate a potential upside of 49.25% from the stock's previous close.

A number of other analysts have also issued reports on BVS. Craig Hallum raised their target price on shares of Bioventus from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Friday, March 6th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Bioventus in a report on Monday, December 29th. Barrington Research increased their price target on Bioventus from $13.00 to $14.00 and gave the stock an "outperform" rating in a research note on Friday, March 6th. Finally, Cantor Fitzgerald upgraded Bioventus to a "strong-buy" rating in a report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $14.00.

Bioventus Price Performance

Shares of BVS traded up $0.12 during trading hours on Friday, reaching $9.38. 39,863 shares of the company traded hands, compared to its average volume of 318,957. The stock has a market capitalization of $779.95 million, a PE ratio of 28.23 and a beta of 0.78. The stock has a fifty day simple moving average of $8.47 and a 200 day simple moving average of $7.65. Bioventus has a fifty-two week low of $5.81 and a fifty-two week high of $9.56. The company has a quick ratio of 1.19, a current ratio of 1.70 and a debt-to-equity ratio of 1.22.

Bioventus (NASDAQ:BVS - Get Free Report) last released its earnings results on Thursday, March 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.02. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. The company had revenue of $157.90 million for the quarter. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Insider Activity

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of the business's stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the sale, the director directly owned 44,997 shares in the company, valued at approximately $395,523.63. The trade was a 21.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 33.00% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BVS. Nantahala Capital Management LLC grew its stake in Bioventus by 28.0% during the second quarter. Nantahala Capital Management LLC now owns 5,280,842 shares of the company's stock worth $34,959,000 after buying an additional 1,155,192 shares during the period. Essex Investment Management Co. LLC purchased a new position in shares of Bioventus in the 4th quarter valued at $2,886,000. Kent Lake PR LLC purchased a new position in shares of Bioventus in the 2nd quarter valued at $2,317,000. Kennedy Capital Management LLC lifted its holdings in shares of Bioventus by 219.6% during the 3rd quarter. Kennedy Capital Management LLC now owns 461,579 shares of the company's stock valued at $3,088,000 after acquiring an additional 317,157 shares in the last quarter. Finally, Meros Investment Management LP acquired a new position in shares of Bioventus during the 4th quarter valued at $2,345,000. 62.94% of the stock is owned by institutional investors and hedge funds.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.